NAICS 325414 - Biological Product (except Diagnostic) Manufacturing
This U.S. industry comprises establishments primarily engaged in manufacturing vaccines, toxoids, blood fractions, and culture media of plant or animal origin (except diagnostic).
Industry trends:
In the field of Biological Product (except Diagnostic) Manufacturing, NAICS 325414, several qualitative trends are shaping the industry. One major trend is the increased focus on personalized medicine and biologics, leading companies to invest heavily in the development of customized treatments tailored to individual genetic profiles. This shift towards precision medicine is anticipated to continue gaining momentum in the near future.
Another emerging trend is the rise of advanced biomanufacturing techniques, including the use of AI and machine learning to optimize production processes, enhance quality control, and reduce costs. These technologies are expected to play a significant role in improving the efficiency and scalability of biologic manufacturing.
Sustainability is also a growing concern in the industry, with companies increasingly adopting eco-friendly practices and materials to minimize their environmental footprint. This includes the development of sustainable bioproduction methods and the use of renewable resources.
Collaborations and partnerships between biotech firms and academic institutions are becoming more common, driving innovation and accelerating the pace of research and development. These alliances are crucial for keeping pace with rapid advancements in biotechnology and for bringing new products to market more swiftly.
Looking ahead, the market for biological products is projected to expand significantly, driven by a growing demand for innovative therapies and an aging population requiring advanced medical treatments. Companies that can successfully integrate cutting-edge technologies, focus on sustainability, and foster strategic partnerships will be well-positioned to thrive in this dynamic landscape.
This industry is comprised of:
Agar culture media manufacturing
Aggressins (except in-vitro) manufacturing
Allergenic extracts (except diagnostic substances) manufacturing
Allergens manufacturing
Antigens manufacturing
Antiserums manufacturing
Antitoxins manufacturing
Antivenoms manufacturing
Bacterial vaccines manufacturing
Bacterins (i.e., bacterial vaccines) manufacturing
Blood derivatives manufacturing
Blood fractions manufacturing
Cholera serums manufacturing
Culture media manufacturing
Gene therapy preparations manufacturing
Hematology products (except diagnostic substances) manufacturing
Plasmas manufacturing
Serums (except diagnostic substances) manufacturing
Toxoids (e.g., diphtheria, tetanus) manufacturing
Tuberculin (i.e., tuberculo-protein derived) manufacturing
Vaccines (i.e., bacterial, virus) manufacturing
Virus vaccines manufacturing
This report includes the ability to segment your Industry by:
- Region
- Employees
- Net Sales
- Company Age
- Total Assets
- Ownership Type
With iCFO You Get
What Is iCFO?
A review and comparison of financial performance of privately-help companies in specified SIC/NAICS industry segment, using industry standard benchmarks.
Sound Business Analysis
Answers come easily with iCFO. Review ROI, sales per employee, profit margins of the top 10%, top 25% and more, to identify areas of concern and opportunity. Examine what if scenarios and P&L impact of reducing costs or adding revenue.
Your Business’ Health In Minutes
It takes only five minutes to enter your data and produce a concise profile of your company’s fiscal state, including critical business ratios focusing on liquidity, profitability, asset efficiency, and growth.